Loading
The first PD-L1 antibody trial treated 207 people across several cancers; melanoma, kidney and lung cancers responded, and none of the 14 pancreatic cancer patients did.
In a multicentre phase 1 trial, intravenous anti-PD-L1 antibody at 0.3 to 10 mg/kg was given every 14 days in 6-week cycles for up to 16 cycles to patients with selected advanced cancers. Of 207 patients, 75 had non-small-cell lung cancer, 55 melanoma, 18 colorectal, 17 renal cell, 17 ovarian, 14 pancreatic, 7 gastric and 4 breast cancer. Grade 3 or 4 treatment-related toxicity occurred in 9%. Objective responses were seen in 9 of 52 melanoma, 2 of 17 renal cell, 5 of 49 lung and 1 of 17 ovarian patients; no pancreatic responses were reported.
The trial that opened the PD-L1 era for other cancers is also the first evidence that pancreatic cancer would be left out of it.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Metastatic pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, PD-1 / PD-L1 immune checkpoint & T-cell activation, Pancreatic ductal adenocarcinoma.
Shares Hot vs cold tumours, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/